v
Lifecycle Management Through the Rx-to-OTC Switch
Table 9-2. Newer Prescription Market Brands..................................................................................140
Table 9-3. Over-the-Counter Allergy Market. .................................................................................143
Table 9-4. Strategic Decision-Making Framework...........................................................................146
Table 9-5. Drug Facts Label Highlights. ..........................................................................................149
Table 9-6. Retail Sales of the Major Switch Products for the 52 Weeks Ending July 2020. .............155
Table 10-1. Example of Prescription and Nonprescription Schedules and Criteria in the UK. ..........163
Table 10-2. Potential Switch Supply Models. .....................................................................................164
Table 10-3. Comparison of Key Enablers and Barriers to Switch Across Seven Countries*...............167
Table 11-1. Typical Consumer Studies. ..............................................................................................181
Table 11-2. Illustrative PERT/PERS Chart. ......................................................................................182
Previous Page Next Page